Clinical trials: Donor Site Complication
Clear Cell Renal Cell Carcinoma (ccRCC)
A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
The purpose of this study is to assess the safety and tolerability of BMS-986527 in participants with Clear Cell Renal Cell Carcinoma (ccRCC)
- Trial name
- NCT07848295
- Testing
- BMS-986527, Nivolumab, Cabozantinib
- Where
- 17 sites in United States, Belgium and 5 more
- Volunteers
- 112 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Superficial Partial Thickness Burn, Skin Graft; Complications
Nitric Oxide Generating Gel Dressing in Patients With Superficial Partial Thickness Wounds
This is a study to assess the safety and efficacy of a nitric oxide (NOx) generating dressing on superficial partial thickness (SPT) wounds. Nitric oxide has a range of effects on the body including vasodilation and angiogenesis.
- Trial name
- ProNOx2 (NCT01983085)
- Testing
- NOx dressing, Standard of Care
- Where
- 2 sites in United Kingdom
- Volunteers
- 13 people
- Sponsor
- Edixomed Ltd
Donor Site Complication
An Investigation to Evaluate a New Donor Site Dressing in Surgical Burn Patients
The investigator will identify the test donor site and test location will be considered on the upper anterior thighs as being the most suitable if available. Circumferential donors will be considered acceptable as well.
- Trial name
- NCT01670201
- Testing
- Mepilex Transfer Ag
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Molnlycke Health Care AB
Palatal Wound
Effects of Topical Hyaluronic Acid Gel on Postoperative Pain and Wound Healing
This clinical study aims to investigate the impact of a topical hyaluronic acid (HA) gel on postoperative pain and wound healing at palatal donor sites in patients undergoing mucogingival procedures involving a de-epithelialized…
- Trial name
- NCT05821725
- Testing
- Hyaluronic acid, Control
- Where
- Brazil
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Donor Site Complication
TWB-103 for Adult Patients With Split-Thickness Skin Graft Donor Site Wounds
Primary objective: 1. To evaluate the safety of TWB-103 in split-thickness skin graft donor site wounds (DSW) for Phase I in terms of Incidence of treatment-related AEs and SAEs (including infections and bleeding) 2.
- Trial name
- NCT02737748
- Testing
- TWB-103 Group
- Where
- 3 sites in Japan, Taiwan
- Volunteers
- 48 people
- Sponsor
- Transwell Biotech Co., Ltd.
Skin Graft Complications
Study to Assess the Safety and Efficacy of DERMASEAL for the Treatment of Split-Thickness Skin Graft Donor Site Wounds
The goal of this study to determine whether the combination biologic/drug DERMASEAL will safely decrease donor wound pain after split-thickness skin graft surgery.
- Trial name
- NCT06134843
- Testing
- DERMASEAL
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Hobart W. Harris